The following protocols have consent changes requiring you to reconsent active patients (unless otherwise noted below).

MCC policy requires all reconsents be completed at the patient’s next scheduled office visit or within two weeks of MCC release of approved consent document, whichever is sooner.

(Please click the links for the available highlighted reconsents & letters.)

January 19th, 2021

• A071701 – ALL Active Patients
• S1933 – ALL Active Patients receiving radiation

January 5th, 2021

• A021703 – ALL Active Patients
• A151804– ALL Patients
• GU007-Phase II – ALL Patients
• GY020– ALL Patients
• S1608 – ALL Active Patients receiving TGR-1202
• S1701 – ALL Active Patients receiving ramucirumab
• S1803-Treatment  – ALL Active Patients receiving daratumumab
• S1900C – ALL Active Patients receiving  talazoparib
• S1929-Treatment  – ALL Active Patients receiving talazoparib
• A221701 –  Investigator Letter and Participant Letter– ALL Patients

December 23rd, 2020

• A021703 – ALL Active Patients

December 15th, 2020

• HN005-Phase II – Active Phase II patients receiving cisplatin (group 1 and group 2)
• S1900B – ALL Active Patients receiving selpercatinib (LOXO-292)

December 1st, 2020

• GY018–ALL Patients

November 17th, 2020

• A011401–ALL Patients
• A021602 Addendum – ALL Patients
• S1900A – Investigator Letter and Participant Letter– Active Cohort 1 Patients

November 3rd, 2020

• GU006 – ALL Patients
• GU008 – Arm 2 Patients
• S1922 – ALL Patients treated with ramucirumab
• A051701 – Investigator Letter and Participant Letter– ALL Patients with DHL
• A221701 –  Investigator Letter and Participant Letter– ALL Active Patients receiving treatment

October 20th, 2020

• A041501–Patients who have not met time-points of Course II on Arm 1 or the 2nd cycle of Arm 2
• CCTG CE.7 Addendum–ALL Patients
• EAY131-H–ALL Patients
• BR004-Dear Participant Letter–ALL Patients
• GU008 –ALL Arm 2 Patients

October 6th, 2020

• EA2187–ALL Patients receiving Pevonedistat
• COVID–19-ALL Patients
• S1403–ALL Patients currently receiving afatinib

September 15th, 2020

• S1800A  – ALL Patients treated with ramucirumab
• S1612 –  Investigator Letter and Participant Letter– All Patients

September 1st, 2020

• No consent changes requiring reconsents.

August 19th, 2020

• AFT-25 – ALL Patients  (Spanish Consent)

August 18th, 2020

• GY014– ALL pts
• A211601 Retrospective – ALL previously enrolled A011502 pts are eligible

August 4th, 2020

• A041702  – ALL patients
• A091802 – Active pts ONLY
• EA9161  – Active pts ONLY

July 21st, 2020

• No consent changes requiring reconsents.

July 7th, 2020

• A221504 Investigator Letter and Participant Letter –Active Patients ONLY

June 16th, 2020

• EA5163 – ALL Patients
• S1609–  Active Patients ONLY

June 2nd, 2020

• A051701 – ALL Patients

May 19th, 2020

• A011202-Addendum Consent – ALL Patients
• BR004-Addendum Consent – ALL Patients

May 7th, 2020

• No consent changes requiring reconsents.

May 5th, 2020

• No consent changes requiring reconsents.

April 23rd, 2020

• No consent changes requiring reconsents.

April 21st, 2020

• GY018 – Investigator Letter & Participant Letter  – Maintenance Therapy pts ONLY

April 7th, 2020

• A031501 – ALL Patients
• A031803 – ALL Patients
• A091605 – ALL Patients
• EA5163 – ALL Patients
• EA6174 – ALL Arm A Patients
• EA9171 – ALL Patients
• GI002 – ALL Arm 3 Patients
• GY004 – Investigator Letter & Participant Letter
• GY016 – ALL Patients
• GY018 – ALL Patients
• LU002 – ALL Patients
• S1404 – Arm 2 pts ONLY
• S1418 – Arm 2 pts ONLY
• S1512
• S1607
• S1800A – Arm B pts ONLY
• S1801

March 17th, 2020

• DT001 – ALL Patients
• GU005 – ALL Patients
• S1815 – Active Arm 1 pts ONLY

March 3rd, 2020

• A071801 – ALL Patients

February 26th, 2020 – CIRB

• S1827 – ALL Patients

February 2020 – Local IRB

• No consent changes requiring reconsents.

February 14th, 2020 – CIRB

• No consent changes requiring reconsents.

January 29th, 2020 – CIRB

• No consent changes requiring reconsents.

January 2020 – Local IRB

• No consent changes  requiring reconsents.

January 15th, 2020 – CIRB

• A171601
• E1910
• EA6134

January 2nd, 2020 – CIRB

• A091605-Physician Letter
• A091605-Patient Letter

December 2019 – Local IRB

• NRG Patient Letter B 31
• NRG B-31 MCC Cover Letter To Pts

December 16th, 2019 – CIRB

• E1A11
• E3A06

December 2nd, 2019 – CIRB

• S1608 – ALL Patients
• S1801

November 2019 – Local IRB

• No consent changes requiring reconsents.

November 15th, 2019 – CIRB

• EA2161
• EA5162
• GY004 – ALL Patients

November 1st, 2019 – CIRB

• A081105 – ALL Patients
• GI002 – Consent Addendum 3
• NSABP B-55: OlympiA Letter To Investigators (Time Sensitive)
• S1602: Investigator Letter And Patient (Arm 3) Information Letter

October 2019 – Local IRB

• No consent changes requiring reconsents.

October 11th, 2019 – CIRB

• A011106

October 4th, 2019 – CIRB

• EA9161

October 1st, 2019 – CIRB

• EAY131-Z1F – ALL Patients
• BR004-Consent Addendum 
• S1613-Treatment
• S1800A

September 2019 – Local IRB

• No consent changes requiring reconsents.

September 16th, 2019 – CIRB

• E1A11: Patient Letter – For Patients on Carfilzomib Only
• E1A11: Investigator Letter 
• S1400F
• S1418

September 3rd, 2019 – CIRB

• S1403

August 2019 – Local IRB

• No consent changes requiring reconsents.

August 15th, 2019 – CIRB

• EA6134 – ALL Patients

August 1st, 2019 – CIRB

• S1815 – ALL Patients

July 23rd, 2019 – CIRB

• S1613-Treatment – ALL Patients

July 2019 – Local IRB

• A031203 – ARM B Only

July 15th, 2019 – CIRB

• A011203: Patient Letter – ALL Patients
• A091401: Patient Letter – ALL Patients
• GY012 – ALL Patients
• S1512
• S1605: Patient Letter – ALL Patients

July 1st, 2019 – CIRB

• A031702
• A031704
• A091401
• E4412-Phase II
• EA6134
• EA6141
• GY005
• S1400I
• S1404
• S1609
• S1616
• S1706

June 2019 – Local IRB

• A031203

June 14th, 2019 – CIRB

• A031701- ALL Patients
• CCTG CE.7 – ALL Patients
• S1607 – ALL Patients

May 31st, 2019 – CIRB

• GY007 Phase II

May 15th, 2019 – CIRB

• A021602 – ALL Patients
• E4412-Phase II – ALL Patients
• EA5152 – ALL Patients
• S1500

May 1st, 2019 – CIRB

• No consent changes requiring reconsents.

April 26th, 2019 – CIRB

• S1602

April 15th, 2019 – CIRB

• A071601
• EA6134
• S1320
• S1500 – Arm 4 ONLY
• S1507

April 2019 – Local IRB

• No consent changes requiring reconsents.

April 1st, 2019 – CIRB

• E1910 – Pts receiving Blinatumomab ONLY

March 15th, 2019 – CIRB

• S1500
• S1500 Investigator & Patient Letters – ALL Patients
• S1612-Memo-Action Letter for Midostaurin  – ALL Patients

March 2019 – Local IRB

• No consent changes requiring reconsents.

March 1st, 2019 – CIRB

• E4512
• S1616

February 2019 – Local IRB

• No consent changes requiring reconsents.

February 15th, 2019 – CIRB

• GY004
• GY005
• GY012
• S1712

February 1st, 2019 – CIRB

• A011502 & Patient Letter
• GY016
• S1500
• S1802
• B-39 Study Closure & Patient Letter
• B-40-Study Closure & Patient Letter

January 2019 – Local IRB

• No consent changes requiring reconsents.

January 15th, 2019 – CIRB

• S1605

January 2nd, 2019 – CIRB

• A221208
• G0262
• S1400K & Physician & Patient Letters – ALL Patients  (Must sign reconsent and receive letter)

[/members_only]